Report Overview
Global Blood Product Market size is expected to be worth around US$ 75.9 Billion by 2034 from US$ 45.3 Billion in 2024, growing at a CAGR of 5.3% during the forecast period 2025 to 2034. In 2024, North America led the market, achieving over 39.9% share with a revenue of US$ 18.1 Billion.
The global Blood Product Market is witnessing steady growth, driven by the increasing demand for blood and blood-derived components in emergency care, trauma management, surgical procedures, cancer treatment, and the management of chronic diseases. Blood products, including red blood cells, platelets, plasma, and other components, play a critical role in modern healthcare by supporting lifesaving transfusions and specialized therapies.
The rising prevalence of hematological disorders, an aging population, and the growing number of complex surgeries are contributing significantly to market expansion. Healthcare systems across developed and emerging economies are investing in advanced blood collection, processing, and storage technologies to ensure a safe and reliable blood supply. Improvements in donor screening, pathogen reduction technologies, and cold chain logistics have further enhanced the quality and safety of blood products.
According to market estimates, the Blood Product Market was valued at US$ 45.3 billion in 2024 and is projected to reach US$ 75.9 billion by 2034, expanding at a CAGR of 5.3% during the forecast period. Continued government initiatives promoting voluntary blood donation, along with expanding healthcare infrastructure and increasing awareness of transfusion safety, are expected to support sustained market growth over the next decade.
Click here for more information: https://market.us/report/blood-product-market/
Key Takeaways
- The global Blood Product Market was valued at US$ 45.3 billion in 2024 and is projected to reach US$ 75.9 billion by 2034, growing at a CAGR of 5.3% during the forecast period.
- By product type, the market is segmented into red blood cells, platelets, and others, with red blood cells leading the market by capturing a 70.4% share in 2023.
- Based on application, the market is categorized into blood stations, hospitals, and others, with blood stations accounting for the largest share of 60.2%.
- North America dominated the global Blood Product Market, holding a 39.9% market share in 2023.
Key Market Segments
- By Product Type
- Red Blood Cells
- Platelets
- Others
- By Application
- Blood Station
- Hospital
- Others
Market Key Players
- Terumo Blood and Cell Technologies
- Takeda
- Octapharma AG
- Kedrion SpA
- Grifols
- CSL
- BPL
- Baxter
Market Dynamics
Driver
The growing need for blood transfusions in emergency care, trauma treatment, major surgeries, and chronic disease management is a key driver of the global Blood Product Market. According to the World Health Organization (WHO), approximately 118.5 million blood donations are collected globally each year, highlighting the essential role of blood products in healthcare. The WHO also reports that 40% of these donations are collected in high-income countries, despite these countries representing a much smaller share of the global population, emphasizing disparities in blood availability.
The U.S. Centers for Disease Control and Prevention (CDC) notes that blood transfusions remain a critical component of healthcare for patients undergoing cancer treatment, organ transplantation, severe trauma, and complex surgical procedures. Furthermore, the National Heart, Lung, and Blood Institute (NHLBI) recognizes red blood cell transfusion as a standard treatment for severe anemia and significant blood loss. Increasing rates of cardiovascular surgeries, road traffic injuries, maternal hemorrhage, and hematologic disorders continue to expand the demand for safe and readily available blood products. Government investments in blood banking infrastructure and voluntary donation programs further support sustained market growth.
Trend
A significant trend in the global Blood Product Market is the increasing adoption of component-based transfusion and advanced blood safety technologies. Rather than transfusing whole blood, healthcare providers increasingly separate donated blood into red blood cells, plasma, platelets, and cryoprecipitate, enabling targeted treatment while maximizing the use of each donation. According to the World Health Organization (WHO), promoting blood component therapy improves clinical outcomes and enhances the efficient utilization of donated blood. The U.S. Food and Drug Administration (FDA) has strengthened regulations governing donor screening, infectious disease testing, and manufacturing standards to improve blood safety.
Advanced nucleic acid testing (NAT), pathogen reduction technologies, and automated blood processing systems are becoming more widely implemented in developed healthcare systems. The CDC also emphasizes continuous surveillance and laboratory testing to minimize transfusion-transmitted infections. Digital blood bank management systems, barcode-based traceability, and improved cold-chain logistics are enhancing inventory management and reducing wastage. These technological advancements are improving patient safety, optimizing blood utilization, and supporting healthcare providers in meeting increasing transfusion requirements worldwide.
Restraint
One of the major restraints affecting the global Blood Product Market is the persistent shortage of voluntary blood donations combined with stringent regulatory requirements governing collection and distribution. According to the World Health Organization (WHO), while around 118.5 million blood donations are collected annually worldwide, many low- and middle-income countries continue to experience shortages due to limited donor participation and inadequate collection infrastructure. Seasonal declines, public health emergencies, and natural disasters can further disrupt blood supplies.
In addition, blood products require rigorous donor eligibility assessments, infectious disease screening, compatibility testing, processing, storage, and transportation under strict regulatory standards established by organizations such as the U.S. Food and Drug Administration (FDA). Maintaining these quality and safety standards significantly increases operational costs for blood centers and hospitals. Blood components also have relatively short shelf lives; for example, platelets generally have a storage life of only about 5 to 7 days, increasing the risk of wastage if demand forecasting is inaccurate. These challenges can limit product availability and increase healthcare system costs.
Opportunity
Growing investments in healthcare infrastructure and government-supported blood donation initiatives present significant opportunities for the global Blood Product Market. The World Health Organization (WHO) encourages countries to establish nationally coordinated blood systems based on 100% voluntary, unpaid blood donation, recognizing this as the safest and most sustainable source of blood supply. Many governments are expanding blood collection centers, improving laboratory testing capabilities, and strengthening cold-chain logistics to increase access to safe blood products. The U.S. Department of Health and Human Services (HHS) and the American Red Cross regularly conduct national awareness campaigns encouraging blood donation to maintain adequate supplies for hospitals and emergency care.
Increasing healthcare access in developing countries is also improving the availability of blood transfusion services for maternal health, trauma care, cancer treatment, and pediatric medicine. Furthermore, advances in pathogen reduction technologies, automated blood collection equipment, and digital inventory management systems are enhancing operational efficiency and patient safety. As populations age and demand for complex medical procedures continues to increase, investments in modern blood banking infrastructure are expected to create substantial long-term growth opportunities for the Blood Product Market.
Conclusion
The global Blood Product Market is expected to witness steady growth, driven by the increasing demand for blood transfusions, rising incidence of chronic diseases, expanding surgical procedures, and growing investments in healthcare infrastructure. Blood products remain essential for the treatment of trauma, cancer, hematological disorders, maternal hemorrhage, and complex surgical interventions, making them indispensable to modern healthcare systems. According to market estimates, the market is projected to grow from US$ 45.3 billion in 2024 to US$ 75.9 billion by 2034, registering a CAGR of 5.3% during the forecast period.
Continuous improvements in blood collection, donor screening, pathogen reduction technologies, and blood component processing are enhancing product safety and availability. Although challenges such as limited voluntary blood donations, strict regulatory requirements, and short shelf life of certain blood components persist, ongoing government initiatives promoting blood donation and investments in advanced blood banking infrastructure are expected to support long-term market growth. As healthcare systems continue to expand and demand for safe blood products rises worldwide, the Blood Product Market is well positioned for sustained development over the coming decade.
Top comments (0)